According to customs statistics, in the first three quarters of this year, the import and export volume of Chinese medicines reached 1.43 billion US dollars, a record high, up 10.7% year-on-year. Among them, the import value was 390 million US dollars, an increase of 18.5%; the export value was 1.04 billion US dollars, an increase of 8.1%. Nonwoven Finished Products,Surgical Drape,Patient Surgical Gown,Sticker Protective Coverall,Delivery Pack,C-Section Pack,Surgical U Drape XINLE HUABAO MEDICAL PRODUCTS CO.,LTD. , https://www.golbaltravel.com
From January to September, the top five markets for Chinese medicine exports were: Japan, Hong Kong, China, Vietnam, and Malaysia. Exports to Japan and Hong Kong are respectively US$200 million and US$150 million, accounting for 19% and 14% of China's exports of Chinese medicine respectively; exports to Malaysia, the United States and Vietnam are growing rapidly; South Korea has set up technical trade barriers. Exports to South Korea have fallen sharply.
The top five markets for imports are: Hong Kong, China, India, Germany and Japan. In addition to importing proprietary Chinese medicines from Hong Kong, most of the products imported from other countries are plant extracts and essential oils, from Latin American countries. Most of the imports are seaweed and algae, fish oil and fat separation products.
The signs of Chinese herbal medicines and decoction exports rebounded significantly. In the first three quarters, the total import and export volume of Chinese herbal medicines and decoction pieces was 189,000 tons, down 5% year-on-year; the import and export value was 440 million US dollars, down 1.7% year-on-year. Among them, the export volume was 156,000 tons, down 3.7% year-on-year; the export value was 370 million US dollars, down 4% year-on-year. The import volume was 34,000 tons, down 10.8% year-on-year; the import value was 67.53 million US dollars, up 13% year-on-year.
From January to September, the main export markets of Chinese herbal medicines and decoction pieces were: Hong Kong, Japan, Vietnam, South Korea, and Taiwan. However, Latin American market demand grew strongly, while exports to Europe fell more.
Guangdong and Guangxi are the main provinces for the export of Chinese herbal medicines and decoction pieces. The largest increase in exports from January to September was in Hubei and Sichuan provinces. The decline in exports was in Beijing, Zhejiang and Jilin. From January to September, there were 960 enterprises exporting Chinese herbal medicines and decoction pieces, a decrease of 13 from the same period of last year, including 652 private enterprises, accounting for 68% of all export enterprises. There are 5 enterprises with export value of more than 10 million US dollars from January to September. The top companies in the export of Chinese herbal medicines and decoction pieces are Guangxi Ningming Import and Export Trade Corporation, Tibet Tangfan Industrial Co., Ltd., China Medicine & Health Products Co., Ltd. and Sichuan Chuancun Chinese Medicine Co., Ltd.; the export growth is faster in Anhui. Yuguang Pharmaceutical Co., Ltd. and Sichuan Chuancun Chinese Medicine Co., Ltd.
The export growth trend of extracts was strong. In the first three quarters, the export growth of plant extracts was strong, and it was the only product with a sharp increase in the export of traditional Chinese medicines. The export value of plant extracts has been ranked first in the export of traditional Chinese medicine products this year, and its proportion has gradually increased, accounting for 46.5% of the total export value of Chinese medicine products, which has become the main driving force for the export of Chinese medicine products.
From January to September, the total import and export of plant extracts reached 35,000 tons, a year-on-year increase of 21%; the total import and export volume was US$596 million, a year-on-year increase of 36%. Among them, the export volume was 26,000 tons, an increase of 9.6% year-on-year; the export volume was 480 million US dollars, an increase of 25.5%.
From the perspective of the product structure of the export, the increase in the amount of export is the natural pigment product. In terms of single varieties, the export value of stevioside increased significantly; the price of high-purity plant extracts increased significantly year-on-year, but the export volume decreased more year-on-year; the export volume and export value of low-purity plant extract products increased slightly.
From January to September, the main markets for China's export of extracts were Japan and the United States, and the markets with faster export growth were India and Malaysia.
Plant extracts are mainly exported to Shandong, Zhejiang and Shanghai. The faster growth of exports was in Shandong, Jiangsu and Yunnan, and the average export price of Guangdong increased rapidly. The three-funded and private enterprises are the main force in the export of extracts, and the export growth of foreign-funded enterprises is as high as 41%. From January to September, a total of 984 companies exported extracts, an increase of 91 over the same period last year, of which 10 companies had exports of more than 10 million US dollars. The top export enterprises are Hebei Chenguang Natural Pigment Co., Ltd., Cangzhou Julong High-tech Food Co., Ltd., Ningbo Lvzhijian Pharmaceutical Co., Ltd., Shanghai Jincun Pharmaceutical Co., Ltd. and Qingdao Runde Biotechnology Co., Ltd. The fastest growth in exports is Qingdao Runde Biotechnology Co., Ltd., Zhangzhou Julong High-Tech Food Co., Ltd. and Zibo Qianqian International Trade Co., Ltd.
In the first three quarters of the import and export of Chinese patent medicines, the import and export volume of Chinese patent medicines was US$246 million, down 6.4% year-on-year. The import and export volume of Chinese patent medicines accounted for 17.15% of the import and export volume of Chinese medicines. The import of Chinese patent medicines was US$126 million, down 8% year-on-year; the export volume was US$120 million, down 4.6% year-on-year.
From January to September, China exported Chinese patent medicines to 120 countries. The main export markets are still traditional markets such as Hong Kong, Japan and the United States.
The main export areas of Chinese patent medicines are Guangdong, Beijing, Fujian and Tianjin, while Hainan and Hebei exports are growing rapidly. State-owned enterprises are the mainstay of Chinese patent medicine exports, accounting for about 58% of the total exports of Chinese patent medicines. From January to September, 526 companies exported Chinese patent medicines, a decrease of 53% year-on-year, of which only two were exported above US$5 million. The three companies that exported from January to September were: Beijing Tongrentang Co., Ltd., Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., and Guangzhou Pharmaceutical Import and Export Corporation. The faster growth of exports is Liang Jiefu (Guangdong) Pharmaceutical Co., Ltd. and Shandong Dong'e Ejiao Co., Ltd.
The export of health care products was stable, and the import and export volume of China's health products was US$150 million in the first three quarters, up 3.74% year-on-year. Among them, the export value was US$63.41 million, a year-on-year increase of 1.2%; the import value was US$86.99 million, a year-on-year increase of 5.7%.
From January to September, China's major export markets for health products are still Japan and the United States, accounting for 62.5% of China's exports of health products. The United States, Canada and Germany have seen a rapid increase in the import of health products in China.
Zhejiang and Guangdong are China's major exporters of health products, and Guangdong and Shandong are the fastest growing exports. The three-funded and private enterprises are the main force in the export of health products, and their exports account for about 85% of domestic exports. From January to September, the enterprises that exported more health products were Guangdong Xianle Pharmaceutical Co., Ltd., Shandong Yuwang Pharmaceutical Co., Ltd., Jiangsu Aoqi Marine Biological Engineering Co., Ltd. and Qinghai Xinyi Industrial Co., Ltd.; Hang Biotechnology Co., Ltd. and Shandong Yuwang Pharmaceutical Co., Ltd.